Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study

BACKGROUND: Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout. We confirmed the serum uric acid lowering effect and safety of dotinurad. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Sano, Takafumi, Sasaki, Tomomitsu, Fushimi, Masahiko, Ohashi, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066091/
https://www.ncbi.nlm.nih.gov/pubmed/31792640
http://dx.doi.org/10.1007/s10157-019-01818-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066091/
https://www.ncbi.nlm.nih.gov/pubmed/31792640
http://dx.doi.org/10.1007/s10157-019-01818-2

Ejemplares similares